WO1996040781A1 - INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2? - Google Patents

INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2? Download PDF

Info

Publication number
WO1996040781A1
WO1996040781A1 PCT/US1996/010186 US9610186W WO9640781A1 WO 1996040781 A1 WO1996040781 A1 WO 1996040781A1 US 9610186 W US9610186 W US 9610186W WO 9640781 A1 WO9640781 A1 WO 9640781A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
cys
compound
asp
fca
Prior art date
Application number
PCT/US1996/010186
Other languages
English (en)
Inventor
Thomas J. Lobl
Shiu-Lan Chiang
Wolfgang Scholz
Nancy Delaet
Pina Cardarelli
Original Assignee
Tanabe Seiyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co., Ltd. filed Critical Tanabe Seiyaku Co., Ltd.
Priority to AU63321/96A priority Critical patent/AU6332196A/en
Priority to US08/738,838 priority patent/US5821329A/en
Priority claimed from US08/738,838 external-priority patent/US5821329A/en
Publication of WO1996040781A1 publication Critical patent/WO1996040781A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés peptidiques cycliques qui modulent l'adhérence cellulaire induite par intégrine. Ces composés peuvent inhiber l'adhérence cellulaire induite à la fois par β1 et β2. L'invention concerne en outre des applications thérapeutiques de ces composés dans le traitement de pathologies apparentées à l'adhérence cellulaire.
PCT/US1996/010186 1995-06-07 1996-06-06 INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2? WO1996040781A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU63321/96A AU6332196A (en) 1995-06-07 1996-06-06 Cyclic peptide inhibitors of beta1 and beta2 integrin-mediated adhesion
US08/738,838 US5821329A (en) 1996-06-06 1996-10-28 Cyclic peptide inhibitors of β1 and β2 integrin-mediated adhesion

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47941195A 1995-06-07 1995-06-07
US08/479,411 1995-06-07
US08/738,838 US5821329A (en) 1996-06-06 1996-10-28 Cyclic peptide inhibitors of β1 and β2 integrin-mediated adhesion

Publications (1)

Publication Number Publication Date
WO1996040781A1 true WO1996040781A1 (fr) 1996-12-19

Family

ID=27046234

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/010186 WO1996040781A1 (fr) 1995-06-07 1996-06-06 INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2?

Country Status (1)

Country Link
WO (1) WO1996040781A1 (fr)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6031072A (en) * 1996-07-12 2000-02-29 Mcgill University Compounds and methods for modulating cell adhesion
US6069163A (en) * 1997-10-21 2000-05-30 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
EP1015479A1 (fr) * 1997-04-11 2000-07-05 Eli Lilly And Company Echantillotheques combinatoires de macrocycles peptidomimetiques et procedes correspondants
US6090841A (en) * 1997-11-21 2000-07-18 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
US6169071B1 (en) 1996-07-12 2001-01-02 Mcgill University Compounds and methods for modulating cell adhesion
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
US6203788B1 (en) 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
US6207639B1 (en) 1996-07-12 2001-03-27 Mcgill University Compounds and methods for modulating neurite outgrowth
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6277824B1 (en) 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6333307B1 (en) 1996-07-12 2001-12-25 Mcgill University Compounds and method for modulating neurite outgrowth
US6346512B1 (en) 1996-07-12 2002-02-12 Mcgill University Compounds and methods for modulating cell adhesion
US6417325B1 (en) 1996-07-12 2002-07-09 Mcgill University Compounds and methods for cancer therapy
US6465427B1 (en) 1996-07-12 2002-10-15 Mcgill University Compounds and methods for modulating cell adhesion
US6511961B1 (en) 1997-11-13 2003-01-28 Toray Industries, Inc. Cyclic peptides and medicinal use thereof
US6562786B1 (en) 1996-07-12 2003-05-13 Mcgill University Compounds and methods for modulating apoptosis
US6610821B1 (en) 1996-07-12 2003-08-26 Mcgill University Compounds and methods for modulating endothelial cell adhesion
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
US6667331B2 (en) 1999-12-28 2003-12-23 Pfizer Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
WO2004041279A1 (fr) 2002-10-30 2004-05-21 Merck & Co., Inc. Modulateurs gamma-aminoamides de l'activite de recepteur de chimiokine
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US7122623B2 (en) 1996-07-12 2006-10-17 Adherex Technologies, Inc. Compounds and methods for modulating cell adhesion
EP2045241A1 (fr) 2002-01-24 2009-04-08 Merck Frosst Canada Ltd. Cycloalkanoindoles substitues par un fluor et leur utilisation comme antagonistes du recepteur de prostaglandine D2
WO2009126920A2 (fr) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Lieurs d'albumine de sérum humain, et ses conjugués
EP2140881A1 (fr) 1999-12-16 2010-01-06 Biogen Idec MA Inc. Procédés de traitement de maladie hémorragique ou ischémique du système nerveux central, utilisant des antagonistes d'intégrine anti alpha 4
WO2010031183A1 (fr) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Dérivés d'indole comme antagonistes du récepteur crth2
WO2010090764A1 (fr) 2009-02-09 2010-08-12 Supergen, Inc. Inhibiteurs pyrrolopyrimidinyle de l'axi kinase
WO2012051036A1 (fr) 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Composés de type quinazolinone convenant comme antagonistes de crth2
WO2012087861A1 (fr) 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinoxalines et aza-quinoxalines comme modulateurs du récepteur crth2
EP2492267A1 (fr) 2009-02-24 2012-08-29 Merck Sharp & Dohme Corp. Dérivés d'indole en tant qu'antagonistes du récepteur CRTH2 en combination avec un second principe actif
EP2510941A2 (fr) 2007-02-20 2012-10-17 Merrimack Pharmaceuticals, Inc. Procédés de traitement de la sclérose en plaques par administration d'une alpha-foetoprotéine combinée à un antagoniste de l'intégrine
WO2012151137A1 (fr) 2011-05-04 2012-11-08 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique contenant une aminopyridine
WO2012174176A1 (fr) 2011-06-17 2012-12-20 Merck Sharp & Dohme Corp. Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2
WO2013052393A1 (fr) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 3-pyridyl carboxamide
WO2018140510A1 (fr) 2017-01-25 2018-08-02 Biogen Ma Inc. Composition et méthodes de traitement d'un accident vasculaire cérébral et d'autres troubles du snc
WO2020143793A1 (fr) 2019-01-10 2020-07-16 石药集团中奇制药技术（石家庄）有限公司 Sels de composé hétérocyclique et utilisation associée

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000995A1 (fr) * 1990-07-09 1992-01-23 Tanabe Seiyaku Co. Ltd. Composes de modulation de l'adherence cellulaire cyclique
WO1994015958A2 (fr) * 1993-01-08 1994-07-21 Tanabe Seiyaku Co., Ltd. Inhibiteurs peptidiques de l'adhesion cellulaire

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000995A1 (fr) * 1990-07-09 1992-01-23 Tanabe Seiyaku Co. Ltd. Composes de modulation de l'adherence cellulaire cyclique
WO1994015958A2 (fr) * 1993-01-08 1994-07-21 Tanabe Seiyaku Co., Ltd. Inhibiteurs peptidiques de l'adhesion cellulaire

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610821B1 (en) 1996-07-12 2003-08-26 Mcgill University Compounds and methods for modulating endothelial cell adhesion
US6914044B2 (en) 1996-07-12 2005-07-05 Mcgill University Compounds and methods for modulating cell adhesion
US6326352B1 (en) 1996-07-12 2001-12-04 Mcgill University Compounds and methods for modulating cell adhesion
US6346512B1 (en) 1996-07-12 2002-02-12 Mcgill University Compounds and methods for modulating cell adhesion
US6780845B2 (en) 1996-07-12 2004-08-24 Mcgill University Compounds and methods for cancer therapy
US6169071B1 (en) 1996-07-12 2001-01-02 Mcgill University Compounds and methods for modulating cell adhesion
US6333307B1 (en) 1996-07-12 2001-12-25 Mcgill University Compounds and method for modulating neurite outgrowth
US6031072A (en) * 1996-07-12 2000-02-29 Mcgill University Compounds and methods for modulating cell adhesion
US6207639B1 (en) 1996-07-12 2001-03-27 Mcgill University Compounds and methods for modulating neurite outgrowth
US6465427B1 (en) 1996-07-12 2002-10-15 Mcgill University Compounds and methods for modulating cell adhesion
US6967238B2 (en) 1996-07-12 2005-11-22 Mcgill University Compounds and methods for modulating cell adhesion
US6417325B1 (en) 1996-07-12 2002-07-09 Mcgill University Compounds and methods for cancer therapy
US7122623B2 (en) 1996-07-12 2006-10-17 Adherex Technologies, Inc. Compounds and methods for modulating cell adhesion
US6562786B1 (en) 1996-07-12 2003-05-13 Mcgill University Compounds and methods for modulating apoptosis
US7138369B2 (en) 1996-07-12 2006-11-21 Mcgill University Compounds and methods for modulating apoptosis
EP1015479A4 (fr) * 1997-04-11 2002-07-24 Lilly Co Eli Echantillotheques combinatoires de macrocycles peptidomimetiques et procedes correspondants
EP1015479A1 (fr) * 1997-04-11 2000-07-05 Eli Lilly And Company Echantillotheques combinatoires de macrocycles peptidomimetiques et procedes correspondants
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6203788B1 (en) 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
US7326686B2 (en) 1997-09-29 2008-02-05 Adherex Inc. Compounds and methods for regulating cell adhesion
US6069163A (en) * 1997-10-21 2000-05-30 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
US6511961B1 (en) 1997-11-13 2003-01-28 Toray Industries, Inc. Cyclic peptides and medicinal use thereof
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
US6090841A (en) * 1997-11-21 2000-07-18 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
US6806255B2 (en) 1998-07-10 2004-10-19 Adherex Technologies, Inc. Compounds and methods for modulating adhesion molecule function
US6472368B1 (en) 1998-07-10 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating adhesion molecule function
US6277824B1 (en) 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
EP2140881A1 (fr) 1999-12-16 2010-01-06 Biogen Idec MA Inc. Procédés de traitement de maladie hémorragique ou ischémique du système nerveux central, utilisant des antagonistes d'intégrine anti alpha 4
EP2332578A1 (fr) 1999-12-16 2011-06-15 Biogen Idec MA Inc. Procédés de traitement de maladie hémorragique ou ischémique du système nerveux central, utilisant des antagonistes de l'intégrine alpha 4
US6668527B2 (en) 1999-12-28 2003-12-30 Pfizer Inc. Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
US6667331B2 (en) 1999-12-28 2003-12-23 Pfizer Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
US6903128B2 (en) 1999-12-28 2005-06-07 Pfizer Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
EP2045241A1 (fr) 2002-01-24 2009-04-08 Merck Frosst Canada Ltd. Cycloalkanoindoles substitues par un fluor et leur utilisation comme antagonistes du recepteur de prostaglandine D2
EP2295409A1 (fr) 2002-01-24 2011-03-16 Merck Frosst Canada Limited Cycloalkanoindoles substitués par un fluor et leur utilisation comme antagonistes du récepteur de prostaglandine D2
WO2004041279A1 (fr) 2002-10-30 2004-05-21 Merck & Co., Inc. Modulateurs gamma-aminoamides de l'activite de recepteur de chimiokine
EP2510941A2 (fr) 2007-02-20 2012-10-17 Merrimack Pharmaceuticals, Inc. Procédés de traitement de la sclérose en plaques par administration d'une alpha-foetoprotéine combinée à un antagoniste de l'intégrine
WO2009126920A2 (fr) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Lieurs d'albumine de sérum humain, et ses conjugués
EP2860260A1 (fr) 2008-04-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Lieurs d'albumine de sérum humain et de leurs conjugués
WO2010031183A1 (fr) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Dérivés d'indole comme antagonistes du récepteur crth2
WO2010090764A1 (fr) 2009-02-09 2010-08-12 Supergen, Inc. Inhibiteurs pyrrolopyrimidinyle de l'axi kinase
EP2492267A1 (fr) 2009-02-24 2012-08-29 Merck Sharp & Dohme Corp. Dérivés d'indole en tant qu'antagonistes du récepteur CRTH2 en combination avec un second principe actif
WO2012051036A1 (fr) 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Composés de type quinazolinone convenant comme antagonistes de crth2
WO2012087861A1 (fr) 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinoxalines et aza-quinoxalines comme modulateurs du récepteur crth2
WO2012151137A1 (fr) 2011-05-04 2012-11-08 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique contenant une aminopyridine
WO2012174176A1 (fr) 2011-06-17 2012-12-20 Merck Sharp & Dohme Corp. Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2
WO2013052393A1 (fr) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 3-pyridyl carboxamide
WO2018140510A1 (fr) 2017-01-25 2018-08-02 Biogen Ma Inc. Composition et méthodes de traitement d'un accident vasculaire cérébral et d'autres troubles du snc
WO2020143793A1 (fr) 2019-01-10 2020-07-16 石药集团中奇制药技术（石家庄）有限公司 Sels de composé hétérocyclique et utilisation associée

Similar Documents

Publication Publication Date Title
WO1996040781A1 (fr) INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2?
WO1994015958A2 (fr) Inhibiteurs peptidiques de l'adhesion cellulaire
US5770565A (en) Peptides for reducing or inhibiting bone resorption
US5192746A (en) Cyclic cell adhesion modulation compounds
JP3248584B2 (ja) フィブロネクチン接着抑制剤
EP0578728B1 (fr) INHIBITEURS DE L'AGREGATION PLAQUETTAIRE PRESENTANT UNE SPECIFICITE ELEVEE POUR GP IIbIIIa
US5510332A (en) Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
AU625801B2 (en) Novel inhibitors of platelet binding
WO1994020534A1 (fr) Peptide vasonatrine et analogues de ce dernier
CA2254995A1 (fr) Composes inhibant l'adhesion cellulaire
AU3411089A (en) Cyclic analogs of atrial natriuretic peptides
US5821329A (en) Cyclic peptide inhibitors of β1 and β2 integrin-mediated adhesion
JPS62129297A (ja) カルシトニン遺伝子関連ペプチド誘導体
AU597919B2 (en) Analogs of atrial natriuretic peptides
CA2122912A1 (fr) Nouveaux peptides, agents inhibant l'agregation plaquettaire, anticoagulants pour la circulation sanguine extracorporelle, inhibiteurs de l'adhesion cellulaire, inhibiteurs de metastases, agents protecteurs des preparations de plaquettes pour la transfusion et ensembles de preparation des plaquettes pour la transfusion a l'aide de ces nouveaux
JPH02500517A (ja) ペプチド化合物
US5814610A (en) Osteogenic growth oligopeptides and pharmaceutical compositions containing them
US6207639B1 (en) Compounds and methods for modulating neurite outgrowth
US6511961B1 (en) Cyclic peptides and medicinal use thereof
EP0018182B1 (fr) Peptides possédant une activité analogue à celle de la thymopoiétine, compositions pharmaceutiques qui les contiennent, et procédé pour les préparer
US5721210A (en) Cyclic cell adhesion modulation compounds
RU2163242C2 (ru) Циклогексапептиды, их смеси, способ их получения
WO1993000108A1 (fr) Nouveaux inhibiteurs d'agregation plaquettaire
Szewczuk et al. Immunosuppressory activity of the cyclodimeric peptide with RGD-sequences.
JP2000503649A (ja) 抗血栓剤および使用法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 08738838

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA